Currently, there are no approved treatments for secondary progressive multiple sclerosis (MS) that stabilize or reverse the neurological disabilities associated with this disease. Oral pirfenidone was found to stabilize and overcome the disabilities in two published independent open-label studies in secondary progressive MS. This led us to study pirfenidone in a phase II double-blind, randomized and controlled, clinical trial in patients with advanced secondary progressive MS for 12 months. Forty-three patients met the eligibility criteria approved by the IRB and accepted by the FDA. Of these patients, 18 were randomly assigned to placebo and 25 patients to oral pirfenidone groups. All eligible patients were included in the statistical analysis of the data according to intention-to-treat principles. Some patients on oral pirfenidone manifested mild drug-related adverse effects, but it was well tolerated overall. By one month, pirfenidone significantly (P<0.05) improved the Scripps Neurological Rating Scale (SNRS) scores, and scores remained significantly improved for 3, 6 and 12 months when compared to the baseline SNRS scores. In contrast, the SNRS scores of patients on oral placebo were not significantly improved at 1, 3, 6 or 12 months of the study, when compared with baseline scores. Oral pirfenidone significantly (P<0.04) reduced the incidence of relapses (27.8% on placebo versus 8.0% on pirfenidone). Furthermore, oral pirfenidone treatment was associated with a marked improvement in bladder dysfunction (40.0% on pirfenidone versus 16.7% on placebo). Expanded Disability Status Scale scores and MRI lesion count were not significantly different in the placebo and pirfenidone groups. These findings indicate a significant effect of pirfenidone on clinical disability and bladder function for secondary progressive MS patients. A major multicentre, double-blind, randomized, controlled trial is justified.
Anderson DW , Ellenberg JH , Leventhal CM , Reingold SC , Rodriguez M , Silberberg DH.Revised estimate of the prevalence of multiple sclerosis in the United States . Ann Neurol1992; 31: 333-336 .
Sadovnick AD , Ebers GC.Epidemiology of multiple sclerosis: a critical over-view . Can J Neurol Sci1993; 20: 17-29 .
4.
Allen I , Brakin B.Pathogenesis of multiple sclerosis-the immune diathesis and the role of viruses . J Neuropathol Exp Neurol1993; 52: 95-105 .
5.
Merril JE , Benveniste EN.Cytokines in inflammatory brain lesions: helpful and harmful . Trends Neurosci1996; 19: 331-338 .
6.
Van Oosten BW , Barkhof F , Scholten PE , von Blomberg BM , Ader HJ , Polman CH.Increased production of tumor necrosis factor alpha and not of interferon-gamma preceding disease activity in patients with multiple sclerosis . Arch Neurol1998; 55: 793-798 .
7.
Gayo A , Mozo L , Suarez A , Tunon A , Lahoz C , Gutierrez C.Interferon beta-1b treatment modulates TNF-alpha and IFN-gamma spontaneous gene expression in MS . Neurology1999; 52: 1764-1770 .
8.
Hofman FM , Hinton DR , Johnson K , Merrill JE.Tumor necrosis factor identified in multiple sclerosis brain . J Exp Med1989; 170: 607-612 .
9.
Akassoglou K , Bauer J , Kassiotis G , Lassman H , Kollias G , Probert L.Transgenic model of TNF-induced demyelination . Adv Exp Med Biol1999; 468: 245-259 .
10.
Robbins DS , Shirazi Y , Drysdale BE , Lieberman A , Shin HS , Shin ML.Production of cytotoxic factor for oligodendrocytes by stimulated astrocytes . J Immunol1987; 139: 2593-2600 .
11.
Sharief MK , Hentges R.Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis . N Engl J Med1991; 325: 467-472 .
12.
Wong D , Dorovini-Zis K.Upregulation of intercellular adhesion molecule-1 (ICAM-1) expression in primary cultures of human brain microvessel endothelial cells by cytokines and lipopolysaccharide . J Neuroimmunol1992; 39: 11-22 .
13.
Satoh JJ , Kastruoff LF , Kim SU.Cytokine-induced expression of intercellular adhesion molecule-1 (ICAM-1) in cultured human oligodendrocytes and astrocytes . J Neuropathol Exp Neurol1991; 50: 215-226 .
Cannella B , Raine CS.The adhesion molecule and cytokine profile of multiple sclerosis lesions . Ann Neurol1995; 37: 424-435 .
16.
Sharief MK , Noori MA , Ciardi M , Cirelli A , Thompson EJ.Increased levels of circulating ICAM-1 in serum and cerebrospinal fluid of patients with active multiple sclerosis. Correlation with TNF-alpha and blood-brain barrier damage . J Neuroimmunol1993; 43: 15-22 .
17.
Lowenstein CJ , Snyder SH.Nitric oxide, a novel biologic messenger [Review] . Cell1992; 70: 705-707 .
18.
Comment on: Proc Natl Acad Sci USA1993; 90: 9808-9812 .
19.
De Groot CJA , Ruuls SR , Theeuwes JWM , Dijkstra CD , Van der Valk, P.Immunocytochemical characterization of the expression of inducible and constitutive isoforms of nitric oxide synthase in demyelinating multiple sclerosis lesions . J Neuropathol Exp Neurol1997; 56: 10-20 .
20.
Cain WC , Stuart RW , Lefkowitz DL , Starnes JD , Margolin SB.Inhibition of tumor necrosis factor and subsequent endotoxin shock by pirfenidone . Int J Immunopharmacol1998; 20: 685-695 .
21.
Hale ML , Margolin SB , Krakauer T , Roy CJ , Stiles BG.Pirfenidone blocks the in vitro and in vivo effects of staphylococcal enterotoxin B . Infect Immunity2002; 70: 2989-2994 .
22.
Nakazato H , Oku H , Yamane S , Tsuruta Y , Suzuki R.A novel anti-fibrotic agent pirfenidone suppresses tumor necrosis factor-alpha at the translational level . Eur J Pharmacol2002; 446: 177-185 .
23.
Walker JE , Margolin SB.Pirfenidone for chronic progressive multiple sclerosis . Mult Scler2001; 7: 305-312 .
24.
Bowen JD , Maravilla K , Margolin SB.Open-label study of pirfenidone in patients with progressive form of multiple sclerosis . Mult Scler2003; 9: 280-283 .
25.
Poser CM , Paty DW , Scheinberg L , McDonald WI , Davis FA , Ebers GCet al.New diagnostic criteria for multiple sclerosis: guidelines for research protocol . Ann Neurol1983; 13: 227-231 .
26.
Goldstein A.Biostatistics: an introductory text. New York, NY: Macmillan , 1964: 234-234.
27.
Sipe JC , Knobler RL , Braheny SL , Rice GP , Panitch HS , Oldstone MB.A neurologic rating scale (NRS) for use in multiple sclerosis . Neurol1984; 34: 1368-1372 .
28.
Kurtzke J.Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS) . Neurology1983; 33: 1444-1452 .
29.
Lang TA , Secic M.How to report statistics in medicine: annotated guidelines for authors, editors, and reviewers. Philadelphia, PA: ACP Medical Writing and Communication, American College of Physicians , 1997: 18-21.
30.
Zar JH.Biostatistical analysis, fourth edition. Upper Saddle River, NJ: Prentice-Hall, Inc. , 1999: 146-148.
31.
Ruuls SR , Bauer J , Sontrop K , Huitinga I , ‘t Hart BA , Dijkstra CD.Reactive oxygen species are involved in pathogenesis of experimental allergic encephalomyelitis in Lewis rats . J Neuroimmunol1995; 56: 207-217 .
32.
Toshniwal PK , Zarling EJ.Evidence for increased lipid peroxidation in multiple sclerosis . Neurochem Res1992; 17: 205-207 .
33.
Das Gupta R , Fowler CJ.Bladder, bowel and sexual dysfunction in multiple sclerosis. Management strategies . Drugs2003; 63: 153-166 .
34.
Bastianello S , Pozzilli C , D’Andrea F , Millefiorini E , Trojano M , Morino Set al.A controlled trial of mitoxantrone in multiple sclerosis: serial MRI evaluation at one year . Can J Neurol Sci1994; 21: 266-270 .
35.
9: 1-14 .
36.
Raeke MK.Multiple sclerosis and magnetic resonance imaging: Advancement in linking the pictures with the progression . Arch Neurol2001; 58: 35-36 .
37.
Miller DH , Grossman RI , Reingold SC , McFarland HF.The role of magnetic resonance techniques in understanding and managing multiple sclerosis . Brain1998; 121: 3-24 .
38.
McFarland HF , Barkhof F , Antel J , Miller DH.The role of MRI as a surrogate outcome measure in multiple sclerosis . Mult Scler2002; 8: 40-51 .
39.
Shamash S , Reichert F , Rotshenker S.The cytokine network of Wallerian degeneration: tumor necrosis factor-a, and inter-leukin-1b . J Neurol Sci2002; 22: 3052-3060 .
40.
Smith ME , van der Maesen K , Somera FP.Macrophage and microglial response to cytokines in vitro: phagocytic activity, proteolytic enzyme release, and free radical production . J Neurosci Res1998; 54: 68-78 .
41.
Myers LW , Ellison GW , Merrill JE , El Hajjar A , St Pierre B , Hijazin Met al.Pentoxyfylline is not a promising treatment for multiple sclerosis in progression phase . Neurology1998; 51: 1483-1486 .
42.
The Lenercept Multiple Sclerosis group and the University of British Columbia MS/MRI analysis group . TNF neutralization in MS: results of a randomized, placebo-controlled multi-center study . Neurology1999: 53: 457-465 .
43.
Giri SN , Wang Q , Xie Y , Largo J , Morin D , Margolin SBet al.Pharmacokinetics and metabolism of a novel antifibrotic drug pirfenidone, in mice following intravenous administration . Biopharmaceut Drug Disp2002; 23: 203-211 .
44.
Beutler B , Bazzoni F.TNF, apoptosis and autoimmunity: a common thread ? Blood Cells Mol Dis1998; 24: 216-230 .
45.
Giri SN , Leonard S , Shi X , Margolin SB , Vallyathan V.Effects of pirfenidone on the generation of reactive oxygen species in vitro . J Environ Pathol Toxicol Oncol1999; 18: 169-177 .
Iyer SN , Du X , Norris C , Margolin SB , Giri SN.Effects of pirfenidone on inflammatory and anti-inflammatory cytokines, CD4 and CD8 T-cells and nitric oxide levels in the bronchoalveolar lavage fluid in bleomycin mouse model of pulmonary fibrosis . Am J Respir Crit Care Med2003; 167: 621-621 .
48.
Huang YM , Xiao BG , Ozenci V , Kouwenhoven M , Teleshova N , Fredrik-Link H.Multiple sclerosis is associated with high levels of circulating dendritic cells secreting pro-inflammatory cytokines . J Neuroimmunol1999; 99: 82-90 .
49.
Iyer SN , Hyde DM , Giri SN.Anti-inflammatory effects of pirfenidone in the bleomycin-hamster model of lung inflammation . Inflammation2000; 24: 477-491 .
50.
Coles AJ , Wing MG , Molyneux P , Paolillo A , Davie CM , Hale Get al.Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis . Ann Neurol1999; 46: 296-304 .
51.
Kaneko M , Inoue H , Nakazawa R , Azuma N , Suzuki M , Yamauchi Set al.Pirfenidone induces intercellular adhesion molecule-1 (ICAM-1) down regulation on cultured human synovial fibroblasts . Clin Exp Immunol1998; 113: 72-76 .
52.
Bauerle PA , Henkel T.Function and activation of NF-kappa B in the immune system . Annu Rev Immunol1994; 12: 141-179 .
53.
Brennan P , O’Neil LAJ.Effects of oxidants and antioxidants on nuclear factor kappa B activation in three different cell lines . Biochim Biophys Acta1995; 1260: 167-175 .
54.
Gurujeyalakshmi G , Wang Y , Giri SN.Taurine and niacin block lung injury and fibrosis by down-regulating bleomycin-induced activation of transcription nuclear factor-kB in mice . J Pharmacol Exp Ther2000; 293: 82-90 .
55.
Schreck R , Albermann K , Bauerle PA.Nuclear factor kappa B: an oxidative stress-responsive transcription factor of eukaryotic cells (a review) . Free Radic Res Commun1992; 17: 221-237 .
56.
Caspary WJ , Lanzo DA , Niziak C.Effect of deoxyribonucleic acid on the production of reduced oxygen by bleomycin and iron . Biochemistry1982; 21: 334-338 .
57.
Beckman JS , Beckman TW , Chen J , Marshall PA , Freeman BA.Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and super-oxide . Proc Natl Acad Sci USA1990; 87: 1620-1624 .
58.
Iyer SN , Du X , Margolin SB , Giri SN.Profiling the effects of pirfenidone on a variety of transcription factors and signal transduction pathways in the bleomycin mouse model of pulmonary fibrosis . Am J Respir Crit Care Med2003; 167: 804-804 .
59.
The IFNβ Multiple Sclerosis Study Group . Interferon-1b is effective in relapsing-remitting multiple sclerosis. 1. Clinical results of a multicenter, randomized, double-blind, placebo, controlled trial . Neurology1993; 43: 655-661 .
60.
Jacobs LD , Beck RW , Simon JH , Kinkel RP , Brownscheidle CM , Murray TJet al.Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG) . Ann Neurol1996; 39: 285-294 .
61.
Comi G , Filippi M , Wolinsky JS.European/Canadian multi-center, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis . Ann Neurol2001; 49: 290-297 .
62.
Paty D.Results of the 3-year, double-blind, placebo-controlled study of interferon beta-1a (Rebif) in secondary progressive MS . Presented at the Ninth Annual Meeting of the European Neurological Society, Milan, Italy, June 5-9, 1999.
63.
Hugh R , SPECTRIMS Group . ‘Relapsing’ versus ‘nonrelapsing’ SPMS: different prognosis and response to interferon therapy in the SPECTRUM study . Neurology2000; 54: A233-A233 abstract.
64.
Parry A , Corckill R , Blamire AM , Palace J , Narayanan S , Arnold Det al.Beta-interferon treatment does not always slow the progression of axonal injury in multiple sclerosis . J Neurol2003; 250: 171-178 .
65.
Hartung HP , Gonsette R , Konig N , Kwiecinski H , Guseo A , Morrissey SPet al.Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomized, multicenter trail . Lancet2002; 360: 2018-2025 .
66.
Avasarala JR , Cross AH , Clifford DB , Singer BA , Siegel BA , Abbey EE.Rapid onset mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis . Mult Scler2003; 9: 59-62 .
67.
Sipe JC , Romine JS , Koziol JA , McMillan R , Zyroff J , Beutler E.Cladribine in treatment of chronic progressive multiple sclerosis . Lancet1994; 344: 9-13 .
